Resumen de acción HLS
HLS Therapeutics Inc, empresa farmacéutica especializada, adquiere y comercializa productos farmacéuticos en los mercados especializados del sistema nervioso central y cardiovascular en Canadá, Estados Unidos e internacionalmente.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Competidores de HLS Therapeutics Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | CA$4.89 |
| 52 Week High | CA$7.12 |
| 52 Week Low | CA$3.34 |
| Beta | 1.14 |
| 1 Month Change | 21.64% |
| 3 Month Change | 16.15% |
| 1 Year Change | -18.50% |
| 3 Year Change | -74.34% |
| 5 Year Change | -70.45% |
| Change since IPO | -57.81% |
Noticias y actualizaciones recientes
After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
Apr 14
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Apr 06Recent updates
After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
Apr 14Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Apr 06Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be
Nov 16Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Sep 13Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
May 05HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Apr 05HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05
Mar 20HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of $0.05
Nov 30Downgrade: Here's How Analysts See HLS Therapeutics Inc. (TSE:HLS) Performing In The Near Term
Nov 11We Think HLS Therapeutics (TSE:HLS) Has A Fair Chunk Of Debt
Sep 14HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Aug 15HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Jul 14HLS Therapeutics (TSE:HLS) Has Announced A Dividend Of CA$0.05
Jun 23HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
Jun 08HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 25HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 10Time To Worry? Analysts Are Downgrading Their HLS Therapeutics Inc. (TSE:HLS) Outlook
Apr 30HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of CA$0.05
Apr 15HLS Therapeutics (TSE:HLS) Has Re-Affirmed Its Dividend Of CA$0.05
Mar 26HLS Therapeutics Inc. (TSE:HLS) Analysts Just Slashed This Year's Estimates
Mar 22HLS Therapeutics (TSE:HLS) Will Pay A Dividend Of CA$0.05
Nov 29HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of CA$0.05
Aug 10Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Apr 30Rentabilidad de los accionistas
| HLS | CA Pharmaceuticals | Mercado CA | |
|---|---|---|---|
| 7D | -4.7% | -3.6% | -2.1% |
| 1Y | -18.5% | 58.0% | 3.6% |
Rentabilidad vs. Industria: HLS obtuvo unos resultados inferiores a los del sector Canadian Pharmaceuticals , que el año pasado arrojó un rendimiento del -32.9%.
Rentabilidad vs. Mercado: HLS obtuvo unos resultados inferiores a los del mercado Canadian, que fue del -0.8% el año pasado.
Volatilidad de los precios
| HLS volatility | |
|---|---|
| HLS Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 14.2% |
| Market Average Movement | 9.2% |
| 10% most volatile stocks in CA Market | 18.4% |
| 10% least volatile stocks in CA Market | 3.1% |
Precio estable de las acciones: El precio de las acciones de HLS ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de HLS (8%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| n/a | 91 | Craig Millian | www.hlstherapeutics.com |
HLS Therapeutics Inc, empresa farmacéutica especializada, adquiere y comercializa productos farmacéuticos en los mercados especializados del sistema nervioso central y cardiovascular en Canadá, Estados Unidos e internacionalmente. La cartera de productos de la empresa incluye Clozaril, un antipsicótico atípico para el tratamiento de los síntomas de la esquizofrenia resistente al tratamiento; y Vascepa, cápsulas de icosapent etílico para enfermedades cardiovasculares. También distribuye los ensayos de laboratorio MyCare para psiquiatría y MyCare Insite, un dispositivo para medir los niveles de fármacos en los pacientes.
Resumen de fundamentos de HLS Therapeutics Inc.
| Estadísticas fundamentales de HLS | |
|---|---|
| Capitalización bursátil | CA$155.92m |
| Beneficios(TTM) | -CA$38.01m |
| Ingresos (TTM) | CA$87.08m |
1.8x
Ratio precio-ventas (PS)-4.1x
Ratio precio-beneficio (PE)¿Está HLS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de HLS | |
|---|---|
| Ingresos | US$63.07m |
| Coste de los ingresos | US$13.20m |
| Beneficio bruto | US$49.88m |
| Otros gastos | US$77.41m |
| Beneficios | -US$27.53m |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.86 |
| Margen bruto | 79.08% |
| Margen de beneficio neto | -43.65% |
| Ratio deuda/patrimonio | 88.8% |
¿Cómo se ha desempeñado HLS a largo plazo?
Ver rendimiento histórico y comparativa